RE:RE:RE:RE:RE:RE:THTX > Is it at all same technology as Trillium (TRIL) I agree TH has all the necessary resources/know-how to perform the early phase of Oncology development, and could probably also handle a Phase II.
After all, they have 3 founders of Katana as full-time employees and 2 as consultants. Top notch experts in the field.
Which brings me to this point: I find the schedule is getting really tight. The November presentation makes the case for a filing of TH-1902 IND in "H2 2020". That was expressed as Q4 in a previous presentation BTW.
So where's that IND? Is it "imminent" too? Where is the associated clinicaltrials.org NCT? It should appear over there I believe, as it's a mandatory part of the IND..
As the Oncology program somehow been softly de-prioritized? That would be a shame and a frightening lack of vision or belief. I have had my fair share of biotechs with ineffectual management letting slip IND deadlines on supposedly promising compounds from a presentation to the next, sometimes for more than 4 years. I'm not going to give Levesque a free pass on this, after the significant over-promise on F8-NASH IND.
qwerty22 wrote:
[..]
My view is they can do what's necessary as long as they have somebody with vision to lead that effort, they have Belivereau as a scientific consultant, I imagine the THTX team are still in some way embedded in his group.
[..]